Business Summary
BioCryst Pharmaceuticals is a global rare disease biotechnology company focused on developing and commercializing small molecule and injectable protein therapeutics, with its lead commercial product ORLADEYO (berotralstat) — the first and only oral once-daily prophylactic therapy for hereditary angioedema (HAE). The company has built a commercial infrastructure around ORLADEYO in the U.S. and select global markets, and in January 2026 completed the acquisition of Astria Therapeutics to add navenibart, a Phase 3 injectable monoclonal antibody for HAE, expanding its rare disease pipeline. BioCryst's strategy centers on leveraging its established commercial platform and structure-guided drug design capabilities to advance both internally discovered and externally acquired rare disease assets.
Products & Services
- ORLADEYO (berotralstat) — Approved oral once-daily HAE prophylaxis for adults/pediatrics ≥12 (U.S., multiple global markets); FDA-approved December 2025 in oral pellet form for pediatric patients aged 2 to <12. Estimated peak global revenue potential of...
AI-generated summary of Item 1 (Business) from the 10-K filed Feb 26, 2026 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.
Across SEC filings
Institutional holders · 13F
Q3 2026| Largest holders | Reported value |
|---|---|
| BlackRock Inc | $202.7M |
| DEERFIELD MANAGEMENT COMPANY L P SERIES C | $129.0M |
| STATE STREET CORPORATION | $102.4M |
| VANGUARD CAPITAL MANAGEMENT LLC | $93.9M |
| TCG Crossover Management LLC | $91.8M |
Annual results · 10-K
Fiscal 2025- Revenue
- $874.8M
- Net income
- $263.9M
As reported in the fiscal 2025 annual report.
Funds & ETFs · N-PORT
Securities
| CUSIP | Security | Type |
|---|---|---|
| 09058V103 | BCRX BIOCRYST PHARMACEUTICALS INC | Common stock |
Insider trades · Form 4
Latest filings
- Jon P Stonehouse 2026-09-02 Award
- Jill C. Milne 2026-09-02 Award
- Vincent Milano 2026-09-02 Award
- Amy E Mckee 2026-09-02 Award
- Steven Frank 2026-09-02 Award
5%+ holders · 13D/G
4 filers| Filer | % of class | Filed |
|---|---|---|
| STATE STREET CORPORATION 13G | 4.8% | 2026-11-10 |
| VANGUARD CAPITAL MANAGEMENT LLC 13G | 5.2% | 2026-04-29 |
| Deerfield Mgmt L P 13G | 6.8% | 2026-02-12 |
| BlackRock Inc 13G | 8.4% | 2025-04-17 |
Latest Schedule 13D or 13G from each filer; stakes a filer has reported closed are left out.